V1RI10 Inhibitors
V1RI10 inhibitors refer to a class of chemical compounds designed to interact with a specific type of receptor or protein within biological systems. These inhibitors are typically characterized by their ability to bind to the active or allosteric sites of their target receptor, which is denoted by the "V1RI10" nomenclature. This binding process involves a complex interplay of molecular interactions, including hydrogen bonding, hydrophobic effects, van der Waals forces, and sometimes covalent bonding. The specificity of V1RI10 inhibitors is a result of their unique molecular structure, which is often tailored to fit the three-dimensional shape of the receptor's binding site with a high degree of precision. The development and refinement of these inhibitors require a deep understanding of the chemistry underlying receptor-ligand interactions, as well as the structural biology of the receptors themselves.
The design of V1RI10 inhibitors is a sophisticated endeavor that utilizes various fields of chemistry, such as organic synthesis, medicinal chemistry, and computational chemistry. Organic synthesis is employed to construct the inhibitor molecule, often involving multi-step synthetic pathways to create a compound with the desired properties. Medicinal chemistry contributes to the optimization of the inhibitor's structure for increased potency and selectivity, while computational chemistry, including molecular modeling and simulation, is used to predict the binding affinity and conformational dynamics of the inhibitors when interacting with the receptor. This multi-disciplinary approach is essential for the fine-tuning of the inhibitors, which must achieve a delicate balance between stability, solubility, and specificity. The molecular architecture of V1RI10 inhibitors is typically complex, incorporating rings, heteroatoms, and various functional groups that are strategically placed to enhance interactions with the receptor and to modulate the inhibitor's overall physicochemical properties.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a potent inhibitor of Raf-1 kinase, which plays a role in the MAPK/ERK signaling pathway. By inhibiting Raf-1, GW5074 can indirectly reduce the activity of downstream targets, potentially leading to decreased activity of V1RI10 if V1RI10 is a downstream effector in this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, a key player in the PI3K/Akt signaling pathway. Inhibition of PI3K can lead to reduced phosphorylation and activation of Akt, which could indirectly affect the activity of V1RI10 if it is regulated by Akt-mediated signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, enzymes that are crucial in the MAPK/ERK pathway. By preventing MEK1/2 activation, U0126 could decrease the phosphorylation of ERK, which may result in the downregulation of V1RI10 activity if it is an ERK pathway component. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that reduces ERK pathway signaling. This compound could decrease V1RI10 activity by impairing the pathway's ability to transmit signals that might normally enhance V1RI10 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a central regulator of cell growth and proliferation. As mTOR can influence various signaling pathways, its inhibition by Rapamycin could lead to reduced V1RI10 activity if V1RI10 is involved in one of these pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, which is implicated in stress and inflammatory responses. If V1RI10 functions are modulated by p38 MAPK activity, then inhibition by SB203580 could lead to a decrease in V1RI10 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, and JNK is part of the MAPK family that regulates various cellular processes. If V1RI10 is a downstream target of JNK signaling, SP600125 could potentially inhibit V1RI10 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, this compound could indirectly reduce V1RI10 activity if V1RI10 is part of the PI3K/Akt pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a Src family kinase inhibitor. Src kinases are involved in numerous signaling pathways, including those that regulate cell proliferation. If V1RI10 is regulated by Src family kinases, PP2 could inhibit its activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK kinases, involved in actin cytoskeleton organization. If V1RI10 is linked to pathways involving ROCK, Y-27632 inhibition could result in decreased V1RI10 activity. | ||||||